Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results, Beats Estimates By $0.09 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL) posted its earnings results on Wednesday. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09, Zacks reports. The firm had revenue of $26.90 million during the quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL traded up $0.03 during mid-day trading on Thursday, hitting $1.79. The stock had a trading volume of 1,010,820 shares, compared to its average volume of 1,520,523. The stock’s fifty day simple moving average is $2.06 and its 200-day simple moving average is $2.87. The firm has a market capitalization of $127.56 million, a price-to-earnings ratio of -0.72 and a beta of 1.75. Zentalis Pharmaceuticals has a 1-year low of $1.61 and a 1-year high of $16.27.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday. Wells Fargo & Company lowered their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. UBS Group dropped their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Wedbush reissued a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.24.

Insider Activity

In other news, insider Ingmar Bruns bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were acquired at an average price of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now owns 36,629 shares in the company, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jan Skvarka purchased 60,000 shares of Zentalis Pharmaceuticals stock in a transaction on Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, with a total value of $103,200.00. Following the transaction, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by company insiders.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.